CBSET Expands Capabilities for High-Speed, High-Resolution 3D Image-Guided Interventions in the Preclinical Development of Cardiovascular Therapies
LEXINGTON, Mass.--CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, has expanded its preclinical development capabilities with the installation of an Innova— Image Guided System 520 from GE Healthcare for interventional cardiology, cardiovascular surgery, and electrophysiology research applications. CBSET is the only non-for-profit, preclinical-focused organization in the worldwide life sciences industry that offers this advanced technology for research purposes.
"We have an unrivaled biomedical facility to advance cutting-edge preclinical science. The addition of the world's most sophisticated 3D imaging capability is in keeping with our mission to provide all of the services needed for the preclinical development of a medical device or drug within a single organization"
Click here for CBSET Press Kit
Among several important features, the Innova IGS 520 Cardiovascular and Hybrid OR Imaging System includes fast-spin rotational angiography as well as 3D imaging of internal structures and devices in one image. The Innova IGS 520 can provide tissue reconstruction based on imaging of bone, soft tissues, and other internal body structures. This system allows fusion of real-time fluoroscopy with 3D anatomy from images generated during the procedure and enables visualization of blood flow in a 3D anatomical setting. This new technology provides more precise positioning of devices and visualization of devices within the anatomy. This state-of-the-art technology is revolutionizing the protocol for complicated cardiac interventions, such as the treatment of aortic or mitral valve replacement/repair procedures, AAA stent graft placement and coronary bifurcation lesions, among others. This new technology further allows combination of rotational angiography with electrophysiology imaging from EP Vision and Heart Vision, which supports localization and positioning of guidewires, ablation catheters, and other devices.
"We have an unrivaled biomedical facility to advance cutting-edge preclinical science. The addition of the world's most sophisticated 3D imaging capability is in keeping with our mission to provide all of the services needed for the preclinical development of a medical device or drug within a single organization," said Peter Markham, president, CEO and a co-founder of CBSET. "Since our founding in 2006, we have helped more than 350 companies attain the highest standards of excellence in preclinical science among a broad array of disciplines and domains. Such an entity did not exist, especially under one roof, prior to CBSET."
CBSET will be exhibiting on Nov. 20 at the 2013 LifeScience Alley Conference in Minneapolis. For more information about CBSET's preclinical development services, please contact: Erica A. Smith, Ph.D., Senior Account Executive, CBSET, +1-781-296-5319, [email protected]
About LifeScience Alley
LifeScience Alley is an international leader in sharing best practices, and is the largest state-based life sciences trade association in the United States. With a 29-year track record of providing valuable services and results-oriented outcomes to its members, LifeScience Alley enables business success through educating workforces, influencing state and federal public policy, supporting advancement in research and technological innovation, and fostering industry connections. The Association's membership employs approximately 250,000 Minnesotans and its reach extends throughout the Midwest and Canada.
About CBSET
CBSET — Concord Biomedical Sciences & Emerging Technologies — is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women's health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products. The company was co-founded in 2006 by Peter Markham, Elazer Edelman, M.D., Ph.D., and Adam Groothuis, Ph.D. CBSET occupies a 35,000-square-foot, state-of-the-art facility near Boston that includes a vivarium, catheterization/imaging labs, surgical suites, dedicated labs for SEM, histopathology/pathology, and drug metabolism and pharmacokinetics. CBSET offers the latest equipment for fluoroscopy, echocardiography (TEE/TTE), electrophysiology, IVUS, optical coherence tomography (OCT), endoscopy/laparoscopy, surgical video recording, histology, microradiography, and SEM (Scanning Electron Microscopy). CBSET's professional staff of 55 FTEs includes Ph.D.s, D.V.M.s and recognized experts in device and drug safety, surgery, imaging, specialized histopathology and pathology, veterinary medicine, pharmacology, lead optimization, pharmacokinetics and drug metabolism, and regulatory consulting. These individuals provide the basis for successful scientific collaborations, rapid concept advancements, unparalleled consulting services, and expert dissemination of information and findings to regulatory and scientific bodies.
Contacts
Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108
President